IWA
TCRT icon

IBEX Wealth Advisors’s Alaunos Therapeutics TCRT Stock Holding History

IBEX Wealth Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17
Closed -$14K – 358
2019
Q2 		$14K Buy
+17
New +$11.7K ﹤0.01% 305

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

IBEX Wealth Advisors's TCRT Position: Q3 2019 in Review

IBEX Wealth Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2019, closing a stake of 17 shares — an estimated $14K sold.

IBEX Wealth Advisors first reported a position in TCRT in Q2 2019 and held it in 1 quarter. The position peaked at $14K in Q2 2019. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

  • IBEX Wealth Advisors reported no remaining Alaunos Therapeutics position as of Q3 2019 after selling out during the quarter.
  • IBEX Wealth Advisors sold 17 Alaunos Therapeutics shares in Q3 2019, an estimated $14K.
  • IBEX Wealth Advisors first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 1 quarter.
  • IBEX Wealth Advisors's Alaunos Therapeutics position peaked at $14K in Q2 2019.
  • 142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on IBEX Wealth Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.